Emglev Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
27, Rue du Faubourg Saint-Jacques, Paris, Île-de-France 75014, FR
Type:
sample
Technology:
sample
sample
About: Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology.
By leveraging its unique proprietary platform, expertise and innovative approach, Emglev unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target.
At Emglev Therapeutics, we have assembled an experienced, interdisciplinary team with a unique vision : to unlock the next level of immunotherapies for the benefit of the patients with high unmet needs.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Emglev Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.